KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Share-based Compensation (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Share-based Compensation data on record, last reported at $39.2 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 23.66% year-over-year to $39.2 million; the TTM value through Dec 2025 reached $158.1 million, down 2.59%, while the annual FY2025 figure was $158.1 million, 2.59% down from the prior year.
  • Share-based Compensation reached $39.2 million in Q4 2025 per EW's latest filing, down from $41.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $44.6 million in Q1 2024 and bottomed at $24.2 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $34.8 million, with a median of $34.4 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: rose 29.14% in 2024, then dropped 14.58% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $24.2 million in 2021, then increased by 15.29% to $27.9 million in 2022, then rose by 9.32% to $30.5 million in 2023, then rose by 3.93% to $31.7 million in 2024, then increased by 23.66% to $39.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $39.2 million in Q4 2025, $41.2 million in Q3 2025, and $37.5 million in Q2 2025.